Skip to main content Accessibility help
  • Print publication year: 2010
  • Online publication date: May 2010

1 - Cardiovascular physiology

from Section 1 - Pathophysiology


1. DespresJP, LemieuxI, BergeronJ, et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008; 28: 1039–49.
2. RosinBL. The progression of cardiovascular risk to cardiovascular disease. Rev Cardiovasc Med 2007; 8 Suppl 4: S3–8.
3. WongC, MarwickTH. Obesity cardiomyopathy: pathogenesis and pathophysiology. Nat Clin Pract Cardiovasc Med 2007; 4: 436–43.
4. WangJ, SongY, WangQ, et al. Causes and characteristics of diabetic cardiomyopathy. Rev Diabet Stud 2006; 3: 108–17.
5. PeetersA, BarendregtJJ, WillekensF, et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med 2003; 138: 24–32.
6. HajerGR, van HaeftenTW, VisserenFL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008; 29; 2959–71.
7. PeregoL, PizzocriP, CorradiD, et al. Circulating leptin correlates with left ventricular mass in morbid (grade III) obesity before and after weight loss induced by bariatric surgery: a potential role for leptin in mediating human left ventricular hypertrophy. J Clin Endocrinol Metab 2005; 90: 4087–93.
8. HarmanceyR, WilsonCR, TaegtmeyerH. Adaptation and maladaptation of the heart in obesity. Hypertension 2008; 52: 181–7.
9. SzmitkoPE, TeohH, StewartDJ, VermaS. Adiponectin and cardiovascular disease: state of the art?Am J Physiol Heart Circ Physiol 2007; 292: H1655–63.
10. OuchiN, ShibataR, WalshK. Cardioprotection by adiponectin. Trends Cardiovasc Med 2006; 16: 141–6.
11. ZhangC. The role of inflammatory cytokines in endothelial dysfunction. Basic Res Cardiol 2008; 103: 398–406.
12. MancoM, Fernandez-RealJM, EquitaniF, et al. Effect of massive weight loss on inflammatory adipocytokines and the innate immune system in morbidly obese women. J Clin Endocrinol Metab 2007; 92: 483–90.
13. RabeK, LehrkeM, ParhoferKG, et al. Adipokines and insulin resistance. Mol Med 2008; 14: 741–51.
14. KrentzAJ. Prevention of cardiovascular complications of the metabolic syndrome: focus on pharmacotherapy. Metab Syndr Relat Disord 2006; 4: 328–41.
15. SchindlerC, The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis?Ther Adv Cardiovasc Dis 2007; 1: 7–26.
16. SeresL, Lopez-AyerbeJ, CollR, et al. Cardiopulmonary function and exercise capacity in patients with morbid obesity. Rev Esp Cardiol 2003; 56: 594–600.
17. LemmensHJ, BernsteinDP, BrodskyJB. Estimating blood volume in obese and morbidly obese patients. Obes Surg 2006; 16: 773–6.
18. CollisT, DevereuxRB, RomanMJ, et al. Relations of stroke volume and cardiac output to body composition: the strong heart study. Circulation 2001; 103: 820–5.
19. StelfoxHT, AhmedSB, RibeiroRA, et al. Hemodynamic monitoring in obese patients: the impact of body mass index on cardiac output and stroke volume. Crit Care Med 2006; 34: 1243–6.
20. LesserGT, DeutschS. Measurement of adipose tissue blood flow and perfusion in man by uptake of 85Kr. J Appl Physiol 1967; 23: 621–30.
21. MesserliFH, VenturaHO, ReisinE, et al. Borderline hypertension and obesity: two prehypertensive states with elevated cardiac output. Circulation 1982; 66: 55–60.
22. FerraroS, Perrone-FilardiP, DesiderioA, et al. Left ventricular systolic and diastolic function in severe obesity: a radionuclide study. Cardiology 1996; 87: 347–53.
23. MesserliFH, ChristieB, DeCarvalhoJG, et al. Obesity and essential hypertension. Hemodynamics, intravascular volume, sodium excretion, and plasma renin activity. Arch Int Med 1981; 141: 81–5.
24. WongC, MarwickTH. Obesity cardiomyopathy: diagnosis and therapeutic implications. Nat Clin Pract Cardiovasc Med 2007; 4: 480–90.
25. LorellBH, CarabelloBA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 2000; 102: 470–9.
26. ArchanS, TollerW. Levosimendan: current status and future prospects. Curr Opin Anaesthesiol 2008; 21: 78–84.
27. BellaJN, DevereuxRB, RomanMJ, et al. Relations of left ventricular mass to fat-free mass and adipose body mass: the strong heart study. The Strong Heart Study Investigators. Circulation 1998; 98: 2538–44.
28. AvelarE, ClowardTV, WalkerJM, et al. Left ventricular hypertrophy in severe obesity: interactions among blood pressure, nocturnal hypoxemia, and body mass. Hypertension 2007; 49: 34–9.
29. de SimoneG, DevereuxRB, RomanMJ, et al. Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults. Hypertension 1994; 23: 600–6.
30. HaqueAK, GadreS, TaylorJ, et al. Pulmonary and cardiovascular complications of obesity: an autopsy study of 76 obese individuals. Arch Pathol Lab Med 2008; 132: 1397–404.
31. LavieCJ, MesserliFH. Cardiovascular adaptation to obesity and hypertension. Chest 1986; 90: 275–9.
32. WoodiwissAJ, LibhaberCD, MajaneOH, et al. Obesity promotes left ventricular concentric rather than eccentric geometric remodeling and hypertrophy independent of blood pressure. Am J Hypertens 2008; 21: 1144–51.
33. de SimoneG. Concentric or eccentric hypertrophy: how clinically relevant is the difference?Hypertension 2004; 43: 714–5.
34. LavieCJ, MilaniRV, VenturaHO, et al. Disparate effects of left ventricular geometry and obesity on mortality in patients with preserved left ventricular ejection fraction. Am J Cardiol 2007; 100: 1460–4.
35. JuricD, WojciechowskiP, DasK, et al. Prevention of concentric hypertrophy and diastolic impairment in aortic-banded rats treated with rosveratrol. Am J Physiol Heart Circ Physiol 2007; 292: H2138–43.
36. PaulusWJ, TschopeC, SandersonJE, et al. How to diagnose diastolic heart failure: a concensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28: 2539–50.
37. PetersonLR. Obesity and insulin resistance: effects on cardiac structure, function, and substrate metabolism. Curr Hypertens Rep 2006; 8: 451–6.
38. PirracchioR, CholleyB, De HertS, et al. Diastolic heart failure in anesthesia and intensive care. Br J Anaesth 2007; 98: 707–21.
39. AurigemmaGP, ZileMR, GaaschWH. Contractile behavior of the left ventricle in diastolic heart failure: with emphasis on regional systolic function. Circulation 2006; 113: 296–304.
40. WongCY, O'MooreSullivan T, LeanoR, et al. Association of subclinical right ventricular dysfunction with obesity. J Am Coll Cardiol 2006; 47: 611–6.
41. ManiscalcoM, ArcielloA, ZeddaA, et al. Right ventricular performance in severe obesity. Effect of weight loss. Eur J Clin Invest 2007; 37: 270–5.
42. GreysonCR. Pathophysiology of right ventricular failure. Crit Care Med 2008; 36(1 Suppl): S57–65.
43. BoutetK, MontaniD, JaisX, et al. Therapeutic advances in pulmonary arterial hypertension. Ther Adv Respir Dis 2008; 2: 249–65.
44. KenchaiahS, EvansS, LevyD, et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347: 305–13.
45. OreopoulosA, PadwalR, Kalantar-ZadehK, et al. Body mass index and mortality in heart failure: a meta-analysis. Am Heart J 2008; 156: 13–22.
46. GustafssonF, KragelundCB, Torp-PedersenC, et al. Effect of obesity and being overweight on long-term mortality in congestive heart failure: influence of left ventricular systolic function. Eur Heart J 2005; 26: 58–64.
47. DublinS, FrenchB, GlazerNL, et al. Risk of new-onset atrial fibrillation in relation to body mass index. Arch Intern Med 2006; 166: 2322–8.
48. WangTJ, PariseH, LevyD, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004; 292: 2471–5.
49. GamiAS, HodgeDO, HergesRM, et al. Obstructive sleep apnea, obesity, and the risk of incidental atrial fibrillation. J Am Coll Cardiol 2007; 49: 565–71.
50. TsangTS, BarnesME, MiyasakaY, et al. Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 years. Eur Heart J 2008; 29: 2227–33.
51. RoyD, TalajicM, NattelS, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008; 358: 2667–77.
52. SomersVK, WhiteDP, AminR, et al. Sleep apnea and cardiovascular disease. Circulation 2008; 118: 1080–111.
53. BradleyTD, FlorasJS. Obstructive sleep apnea and its cardiovascular consequences. Lancet 2009; 373: 82–93.
54. Valencia-FloresM, OreaA, CastanoVA, et al. Prevalence of sleep apnea and electrocardiographic disturbances in morbidly obese patients. Obes Res 2000; 8: 262–9.
55. PapaioannouA, MichaloudisD, FraidakisO, et al. Effects of weight loss on QT interval in morbidly obese patients. Obes Surg 2003; 13: 869–73.
56. ArtzM, BradleyTD. Treatment of sleep apnea in heart failure. Am J Respir Crit Care Med 2006; 173: 1300–8.
57. IkonomidisI, MazarakisA, PapadopoulosC, et al. Weight loss after bariatric surgery improves aortic elastic properties and left ventricular function in individuals with morbid obesity: a 3-year follow-up study. J Hypertens 2007; 25: 439–47.
58. GoodD, MorseSA, VenturaHO, et al. Obesity, hypertension, and the heart. J Cardiometab Syndr 2008; 3: 168–72.
59. GonzagaCC, CalhounDA. Resistant hypertension and hyperaldosteronism. Curr Hypertens Rep 2008; 10: 496–503.
60. WittelesRM, FowlerMB. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol 2008; 51: 93–102.
61. IoannidisI. The road from obesity to type 2 diabetes. Angiology 2008; 59(2 Suppl): 39S–43S.
62. PetersonLR, HerreroP, SchechtmanKBet al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 2004; 109: 2191–6.
63. GrundySM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 2002; 105: 2696–8.
64. JensenMK, ChuiveSE, RimmEB, et al. Obesity, behavioral lifestyle factors, and risk of acute coronary events. Circulation 2008; 117: 3062–9.
65. FraleyMA, BirchemJA, SenkottaiyanN, et al. Obesity and the electrocardiogram. Obes Rev 2005; 6: 275–81.
66. AshrafianH, le RouxCW, DarziA, et al. Effects of bariatric surgery on cardiovascular function. Circulation 2008; 118: 2091–102.
67. RistowB, RabkinJ, HaeussleinE. Improvement in dilated cardiomyopathy after bariatric surgery. J Card Fail 2008; 14: 198–202.
68. Di BelloV, SantiniF, Di CoriA, et al. Effects of bariatric surgery on early myocardial alterations in adult severely obese subjects. Cardiology 2008; 109: 241–8.
69. MuscelliE, CamastraS, CatalanoC, et al. Metabolic and cardiovascular assessment in moderate obesity: effect of weight loss. J Clin Endocrinol Metab 1997; 82: 2937–43.
70. SugermanHJ, BaronPL, FairmanRP, et al. Hemodynamic dysfunction in obesity hypoventilation syndrome and the effects of treatment with surgically induced weight loss. Ann Surg 1988; 207: 604–13.
71. WillensHJ, ChakkoSC, ByersP, et al. Effects of weight loss after gastric bypass on right and left ventricular function assessed by tissue Doppler imaging. Am J Cardiol 2005; 95: 1521–4.